Concise review: Growth differentiation factor 15 in pathology: A clinical role?

Stem Cells Translational Medicine

Volumn 2, Issue 12, 2013, Pages 946-952

  Corre, Jill ^a,b,c   Hébraud, Benjamin ^a,c   Bourin, Philippe ^d  

^a Intergroupe Francophone du Myélome   (France)

^b INSERM   (France)

^c CHU PURPAN   (France)

^d CSA21   (France)

Author keywords

Cancer; Clinical translation; Drug target; Malignancy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BORTEZOMIB; C REACTIVE PROTEIN; CD34 ANTIGEN; DOCETAXEL; GROWTH DIFFERENTIATION FACTOR 15; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOXANTRONE; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE ATROPHY; CARDIOLOGY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; ERYTHROPOIESIS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; MORTALITY; NEOPLASM; NONHUMAN; PATHOLOGY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84888421123     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0055     Document Type: Article

References (72)

1. Bootcov MR, Bauskin AR, Valenzuela SM et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-_ superfamily. Proc Natl Acad Sci USA 1997;94: 11514-11519.
2. Eling TE, Baek SJ, Shim M et al. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 2006;39: 649-655.
3. Bauskin AR, Brown DA, Junankar S et al. The propeptide mediates formation of stromal stores of PROMIC-1: Role in determining prostate cancer outcome. Cancer Res 2005;65: 2330-2336.
4. Fairlie WD, Zhang H, Brown PK et al. Expression of a TGF-beta superfamily protein, macrophage inhibitory cytokine-1, in the yeast Pichia pastoris. Gene 2000;254: 67-76.
5. Breit SN, Johnen H, Cook AD et al. The TGF-_ superfamily cytokine, MIC-1/GDF15: A pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 2011;29:187-195.
6. Hromas R, Hufford M, Sutton J et al. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1997;1354:40-44.
7. Soucek K, Slabakova E, Ovesna P et al. Growth/differentiation factor-15 is an abundant cytokine in human seminal plasma. Hum Reprod 2010;25:2962-2971.
8. Moore AG, Brown DA, FairlieWDet al. The transforming growth factor-_ superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000;85:4781-4788.
9. Tong S, Marjono B, Brown DA et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet 2004;363:129-130.
10. Wiklund FE, Bennet AM, Magnusson PK et al. Macrophage inhibitory cytokine-1 (MIC-1/ GDF15): A new marker of all-cause mortality. Aging Cell 2010;9:1057-1064.
11. Daniels LB, Clopton P, Laughlin GA et al. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: The Rancho Bernardo Study. Circulation 2011;123: 2101-2110.
12. Basil CF, Zhao Y, Zavaglia K et al. Common cancer biomarkers. Cancer Res 2006;66: 2953-2961.
13. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 2010;224:626-635.
14. Welsh JB, Sapinoso LM, Su AI et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-5978.
15. Buckhaults P, Rago C, St Croix B et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001;61:6996-7001.
16. Koopmann J, Zhang Z, White N et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-868.
17. Zhang L, Yang X, Pan H-Y et al. Expression of growth differentiation factor 15 is positively correlated with histopathological malignant grade and in vitro cell proliferation in oral squamous cell carcinoma. Oral Oncol 2009;45:627-632.
18. Boyle GM, Pedley J, Martyn AC et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 2009;129:383-391.
19. Park YJ, Lee H, Lee JH. Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. BMB Rep 2010;43: 91-96.
20. Roth P, Junker M, Tritschler I et al. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 2010;16:3851-3859.
21. Lee DH, Yang Y, Lee SJ et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003;63:4648-4655.
22. Corre J, Mahtouk K, Attal M et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007;21: 1079-1088.
23. Li PX, Wong J, Ayed A et al. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells toDNAdamage and p53 overexpression. J Biol Chem 2000;275: 20127-20135.
24. Baek SJ, Okazaki R, Lee SH et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006;131:1553-1560.
25. Baek SJ, Wilson LC, Eling TE. Resveratrol enhances the expression of non-steroidal antiinflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002;23:425-434.
26. Baek SJ, Kim JS, Moore SM et al. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005;67:356-364.
27. Yamaguchi K, Lee SH, Eling TE et al. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/ AKT/GSK-3beta pathway. J Biol Chem 2004;279:49617-49623.
28. Corre J, Labat E, Espagnolle N et al. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res 2012;72:1395-1406.
29. Huang C-Y, Beer TM, Higano CS et al. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: Identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 2007;13:5825-5833.
30. Subramaniam S, Strelau J, Unsicker K. Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways. J Biol Chem 2003;278: 8904-8912.
31. Johnen H, Lin S, Kuffner T et al. Tumorinduced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007;13:1333-1340.
32. Kim KK, Lee JJ, Yang Y et al. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 2008;29:704-712.
33. Xu J, Kimball TR, Lorenz JN et al. GDF15/ MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006;98:342-350.
34. de Jager SCA, Bermudez B, Bot I et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Exp Med 2011;208:217-225.
35. Huh SJ, Chung CY, Sharma A et al. Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol 2010;176:2948-2957.
36. Albertoni M, Shaw PH, Nozaki M et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002;21: 4212-4219.
37. Liu T, Bauskin AR, Zaunders J et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;63:5034-5040.
38. Senapati S, Rachagani S, Chaudhary K et al. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 2010;29:1293-1302.
39. Wakchoure S, Swain TM, Hentunen TA et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate 2009;69:652-661.
40. Hinoi E, Ochi H, Takarada T et al. Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia. J Bone Miner Res 2012;27:938-949.
41. Martin SK, Diamond P, Gronthos S et al. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011;25: 1533-1542.
42. Brown DA, Ward RL, Buckhaults P et al. MIC-1 serum level and genotype: Associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642-2650.
43. Ding Q, Mracek T, Gonzalez-Muniesa P et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 2009;150:1688-1696.
44. Brown DA, Lindmark F, Stattin P et al. Macrophage inhibitory cytokine 1: A new prognostic marker in prostate cancer. Clin Cancer Res 2009;15:6658-6664.
45. Koopmann J, Rosenzweig CN, Zhang Z et al. Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;12:442-446.
46. Staff AC, Bock AJ, Becker C et al. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 2010; 118:237-243.
47. Staff AC, Trovik J, Zahl EAG et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res 2011;17:4825-4833.
48. Kluger HM, Hoyt K, Bacchiocchi A et al. Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 2011; 17:2417-2425.
49. Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-1101.
50. Tamary H, Shalev H, Perez-Avraham G et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008;112: 5241-5244.
51. Ramirez JM, Schaad O, Durual S et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol 2009;144: 251-262.
52. Finkenstedt A, Bianchi P, Theurl I et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol 2009;144:789-793.
53. Bruns I, Cadeddu R-P, Brueckmann I et al. Multiple myeloma-related deregulation of bone marrow-derived CD34_ hematopoietic stem and progenitor cells. Blood 2012;120: 2620-2630.
54. Brown DA, Breit SN, Buring J et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: A nested case-control study. Lancet 2002;359:2159-2163.
55. Kempf T, von Haehling S, Peter T et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1054-1060.
56. Kempf T, Bjorklund E, Olofsson S et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 2007;28:2858-2865.
57. Wollert KC, Kempf T, Peter T et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;115: 962-971.
58. Lankeit M, Kempf T, Dellas C et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008;177:1018-1025.
59. Nickel N, Kempf T, Tapken H et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:534-541.
60. Foley PW, Stegemann B, Ng K et al. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J 2009;30:2749-2757.
61. Norozi K, Buchhorn R, Yasin A et al. Growth differentiation factor 15: An additional diagnostic tool for the risk stratification of developing heart failure in patients with operated congenital heart defects? Am Heart J 2011;162:131-135.
62. Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: An update. Curr Heart Fail Rep 2012;9:337-345.
63. Johnen H, Kuffner T, Brown DA et al. Increased expression of the TGF-b superfamily cytokine MIC-1/GDF15 protects ApoE(_/_) mice from the development of atherosclerosis. Cardiovasc Pathol 2012;21:499-505.
64. Bonaterra GA, Zugel S, Thogersen J et al. Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury. J Am Heart Assoc 2012;1:e002550.
65. Kempf T, Eden M, Strelau J et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98:351-360.
66. Xu X, Li Z, Gao W. Growth differentiation factor 15 in cardiovascular diseases: From bench to bedside. Biomarkers 2011;16:466-475.
67. Brown DA, Moore J, Johnen H et al. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis. A potential marker of erosive joint destruction. Arthritis Rheum 2007;56: 753-764.
68. Breit SN, Carrero JJ, Tsai VW et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant 2012;27:70-75.
69. Hellemons ME, Mazagova M, Gansevoort RT et al. Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care 2012;35:2340-2346.
70. Mensching L, Börger AK, Wang X et al. Local substitution of GDF-15 improves axonal and sensory recovery after peripheral nerve injury. Cell Tissue Res 2012;350:225-238.
71. Hsiao EC, Koniaris LG, Zimmers-Koniaris T et al. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 2000;20:3742-3751.
72. Strelau J, Strzelczyk A, RusuPet al. Progressive postnatal motoneuron loss in mice lacking GDF-15. J Neurosci 2009;29:13640-13648.